EU Lands Deal to Secure 8M Vaccine Doses Against Mpox, Smallpox
Spanning four years and building on a 2022 accord for the same inoculant, the landmark pact encompasses 20 member states and positions Europe to mount rapid responses against cross-border health emergencies. The deal empowers individual nations to source vaccines for domestic requirements while simultaneously bolstering the EU's rescEU strategic medical reserves.
"Mpox outbreaks remain a simmering threat," Commissioner for Equality, Preparedness and Crisis Management Hadja Lahbib said. "This joint procurement boosts our readiness and guarantees security of supply against mpox and smallpox. Vigilance and preparedness are essential to safeguard health security across Europe."
The coordinated procurement reflects an escalating commitment among EU states to consolidate purchasing power—a strategy yielding cost advantages and supply reliability as global vaccine competition intensifies, the European Commission explained.
Orchestrated through the Health Emergency Preparedness and Response Authority (HERA), the initiative exemplifies the EU's structural transformation toward centralized reserves and unified acquisition frameworks—a hard-won lesson from the COVID-19 pandemic's supply chain fractures.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
